CRISPR Therapeutics AG

CRISPR Therapeutics AG is a gene editing company focused on developing gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 platform. The CRISPR/Cas9 technology enables precise alteration of specific sequences of genomic DNA. The company's therapeutic programs span several disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo therapies, and type 1 diabetes. Its lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating transfusion-dependent beta-thalassemia, severe sickle cell disease, and other hemoglobinopathies. Additionally, CRISPR Therapeutics is developing CAR T cell therapies such as CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmune indications, as well as in vivo programs like CTX310 and CTX320 for cardiovascular disease.

CRISPR Therapeutics AG is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CRSP. The company's shares are traded in US Dollars (USD). As a Swiss company with a US listing, it provides investors access to its gene editing pipeline through a major US exchange, with all financial reporting and trading conducted in USD.

CRISPR Therapeutics AG operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies based on gene editing technology. The company's work involves cutting-edge research and development of gene-based medicines, placing it at the forefront of the biotech field, particularly in the area of CRISPR/Cas9 gene editing.

CRISPR Therapeutics AG is headquartered in Switzerland, and it serves global markets, with a particular focus on the United States as indicated by its US region classification and Nasdaq listing. The company develops therapies for serious human diseases, including hemoglobinopathies, oncology, autoimmune indications, cardiovascular disease, and type 1 diabetes. Its strategic partnerships and clinical programs target patients worldwide, leveraging its CRISPR/Cas9 platform to address unmet medical needs across multiple therapeutic areas.

CRISPR Therapeutics AG has a diverse portfolio of therapeutic programs. Its lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease. The company also develops CAR T cell therapies: CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmune indications. In the in vivo space, it has CTX310 and CTX320 for cardiovascular disease by disrupting angiopoietin-like protein 3 and lipoprotein(a), respectively. Additionally, CTX211 is an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for type 1 diabetes. These programs reflect the company's focus on leveraging its CRISPR/Cas9 platform across multiple disease areas.